Sunday, June 21, 2026
Zealand Pharma wants a former Novo leader on its board. The move could bring Novo's drug-making know-how to Zealand's obesity peptide work.
Boehringer Ingelheim and Zealand Pharma's obesity drug showed results in Phase 3 testing that look more like Novo Nordisk's Wegovy than expected. The finding matters because it helps doctors and investors understand how well the new drug works compared to existing weight-loss medicines.
Boehringer and Zealand's new weight-loss drug looks more like Wegovy than a stronger rival. That makes it harder to stand out in a crowded market led by Novo and Lilly.
A drug made by Boehringer and Zealand Pharma helped patients lose 16.6% of their body weight in a late-stage trial. This is a major test before the companies can ask the FDA to approve the drug.
Survodutide hit 16.6% weight loss in a late-stage trial. That gives Boehringer and Zealand a real shot at competing with Lilly and Novo for obesity patients.
Boehringer Ingelheim's survodutide, a dual-action weight-loss drug, helped people lose 16.6% of their body weight in a Phase 3 trial (a large final test before approval). The drug also improved other health markers related to weight and metabolism.
Survodutide helped patients lose 16.6% of their weight. That puts Boehringer and Zealand in the same league as Wegovy and Zepbound for obesity care.